Compartir
Título
Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2
Autor(es)
Palabras clave
SARS-CoV-2
DNA vaccine
S protein
N protein
Mouse model
pPAL
Furin
Clasificación UNESCO
3209 Farmacología
6310.03 Enfermedad
Fecha de publicación
2022
Editor
Board
Citación
Alcotea, P.J., Larraga, J., Rodríguez Martín, D., Alonso, A., Loayza, F.J., Rojas, J.M., Ruiz García, S., Louloudes Lázaro, A., Carlón, A.B., Sánchez Cordón, P.J., Nogales Altozano, P., Redondo, N., Manzano, M., Lozano, D., Palomero Labajos, J., Montoya, M., Vallet Regí, M., Martín, V., Sevilla, N., Larraga, V. (2022). Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2., Frontiers in Immunology. 13 pp 1-17. https://doi.org/10.3389/fimmu.2022.1023255
Resumen
[EN] SARS-CoV-2 vaccines currently in use have contributed to controlling the
COVID-19 pandemic. Notwithstanding, the high mutation rate, fundamentally
in the spike glycoprotein (S), is causing the emergence of new variants. Solely
utilizing this antigen is a drawback that may reduce the efficacy of these
vaccines. Herein we present a DNA vaccine candidate that contains the genes
encoding the S and the nucleocapsid (N) proteins implemented into the nonreplicative mammalian expression plasmid vector, pPAL. This plasmid lacks
antibiotic resistance genes and contains an alternative selectable marker for
production. The S gene sequence was modified to avoid furin cleavage (Sfs).
Potent humoral and cellular immune responses were observed in C57BL/6J
mice vaccinated with pPAL-Sfs + pPAL-N following a prime/boost regimen by
the intramuscular route applying in vivo electroporation. The immunogen fully protected K18-hACE2 mice against a lethal dose (105 PFU) of SARS-CoV-2.
Viral replication was completely controlled in the lungs, brain, and heart of
vaccinated mice. Therefore, pPAL-Sfs + pPAL-N is a promising DNA vaccine
candidate for protection from COVID-19.
URI
DOI
10.3389/FIMMU.2022.1023255
Versión del editor
Collections